GENEVA (Reuters) – Swiss drugmaker Novartis mentioned on Tuesday it was suspending capital investments, media promoting, and different promotional actions in Russia however remained dedicated to offering entry to its medication there.
“Novartis condemns the battle in Ukraine,” it mentioned in an announcement, including that “whereas we stay dedicated to offer entry to our medication in Russia, we responsibly pause the initiation of recent scientific trials and the enrolment of recent examine contributors in present trials.”
The transfer by Novartis follows related steps by different drugmakers following sanctions towards Moscow for its invasion of Ukraine.
Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or harm on account of reliance on the knowledge together with information, quotes, charts and purchase/promote indicators contained inside this web site. Please be totally knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding varieties doable.